| Company | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
|---|---|---|---|---|---|---|---|
| EXELIXIS, INC. | EVP and CFO | Common Stock | 967,842 | $44,520,732 | $46 | 16 May 2025 | Direct |
| EXELIXIS, INC. | EVP and CFO | Common Stock | 2,723 | $104,971 | $38.55 | 15 May 2025 | By 401(k) |
| Quince Therapeutics, Inc. | Director | Director Stock Option (Right to Buy) | 27,000 | 04 Jun 2025 | Direct | ||
| Quince Therapeutics, Inc. | Director | Employee Stock Option (right to buy) | 27,000 | 05 Jun 2024 | Direct | ||
| EXELIXIS, INC. | EVP and CFO | Option (right to buy) | 0 | 16 May 2025 | Direct |
| Symbol | Company | Period | Transactions | Value $ | Form Type | Role | Filing Time |
|---|---|---|---|---|---|---|---|
| QNCX | Quince Therapeutics, Inc. | 04 Jun 2025 | 1 | $0 | 4 | Director | 06 Jun 2025, 17:36 |
| EXEL | EXELIXIS, INC. | 15 May 2025 | 4 | -$4,569,492 | 4 | EVP and CFO | 16 May 2025, 20:58 |
| EXEL | EXELIXIS, INC. | 31 Mar 2025 | 1 | $0 | 4 | EVP and CFO | 31 Mar 2025, 19:42 |
| EXEL | EXELIXIS, INC. | 26 Feb 2025 | 1 | $0 | 4 | EVP and CFO | 28 Feb 2025, 20:34 |
| EXEL | EXELIXIS, INC. | 24 Feb 2025 | 3 | -$508,304 | 4 | EVP and CFO | 26 Feb 2025, 20:00 |
| EXEL | EXELIXIS, INC. | 15 Feb 2025 | 1 | -$755,685 | 4 | EVP and CFO | 19 Feb 2025, 20:32 |
| EXEL | EXELIXIS, INC. | 16 Jan 2025 | 2 | -$1,339,819 | 4 | EVP and CFO | 17 Jan 2025, 21:45 |
| QNCX | Quince Therapeutics, Inc. | 02 Jan 2025 | 1 | $0 | 4 | Director | 08 Jan 2025, 19:29 |
| EXEL | EXELIXIS, INC. | 15 Nov 2024 | 1 | -$613,585 | 4 | EVP and CFO | 19 Nov 2024, 20:03 |
| EXEL | EXELIXIS, INC. | 09 Aug 2024 | 3 | -$347,500 | 4 | EVP and CFO | 09 Aug 2024, 19:31 |
| QNCX | Quince Therapeutics, Inc. | 05 Jun 2024 | 1 | $0 | 4 | Director | 07 Jun 2024, 21:00 |
| EXEL | EXELIXIS, INC. | 15 May 2024 | 3 | -$636,206 | 4 | EVP and CFO | 17 May 2024, 19:57 |
| EXEL | EXELIXIS, INC. | 23 Feb 2024 | 1 | $0 | 4 | EVP and CFO | 27 Feb 2024, 18:58 |
| EXEL | EXELIXIS, INC. | 11 Jan 2024 | 2 | -$499,765 | 4 | EVP and CFO | 16 Jan 2024, 20:50 |
| EXEL | EXELIXIS, INC. | 06 Sep 2023 | 2 | -$381,863 | 4 | EVP and CFO | 08 Sep 2023, 21:26 |
| EXEL | EXELIXIS, INC. | 15 Aug 2023 | 1 | -$173,671 | 4 | EVP and CFO | 17 Aug 2023, 20:19 |
| EXEL | EXELIXIS, INC. | 03 Aug 2023 | 6 | -$702,600 | 4 | EVP and CFO | 07 Aug 2023, 21:20 |
| QNCX | Quince Therapeutics, Inc. | 24 May 2023 | 1 | $0 | 4 | Director | 26 May 2023, 17:53 |
| EXEL | EXELIXIS, INC. | 15 May 2023 | 2 | -$353,794 | 4 | EVP and CFO | 17 May 2023, 20:16 |
| EXEL | EXELIXIS, INC. | 03 Apr 2023 | 1 | $0 | 4 | EVP and CFO | 05 Apr 2023, 20:25 |
| EXEL | EXELIXIS, INC. | 15 Feb 2023 | 1 | -$95,426 | 4 | EVP and CFO | 17 Feb 2023, 20:42 |
| EXEL | EXELIXIS, INC. | 15 Nov 2022 | 1 | -$134,916 | 4 | EVP and CFO | 17 Nov 2022, 19:38 |
| EXEL | EXELIXIS, INC. | 11 Aug 2022 | 3 | -$1,542,382 | 4 | EVP and CFO | 12 Aug 2022, 20:23 |
| EXEL | EXELIXIS, INC. | 03 Aug 2022 | 2 | -$173,510 | 4 | EVP and CFO | 05 Aug 2022, 21:48 |
| QNCX | Cortexyme, Inc. | 08 Jun 2022 | 1 | $0 | 4 | Director | 09 Jun 2022, 20:48 |
| EXEL | EXELIXIS, INC. | 15 May 2022 | 1 | -$169,555 | 4 | EVP and CFO | 17 May 2022, 20:23 |
| EXEL | EXELIXIS, INC. | 04 Mar 2022 | 1 | $0 | 4 | EVP and CFO | 08 Mar 2022, 19:57 |
| EXEL | EXELIXIS, INC. | 15 Feb 2022 | 2 | -$340,698 | 4 | EVP and CFO | 17 Feb 2022, 19:04 |
| EXEL | EXELIXIS, INC. | 15 Dec 2021 | 2 | -$87,227 | 4 | EVP and CFO | 17 Dec 2021, 19:32 |
| EXEL | EXELIXIS, INC. | 15 Nov 2021 | 3 | -$1,044,605 | 4 | EVP and CFO | 17 Nov 2021, 19:39 |
| EXEL | EXELIXIS, INC. | 30 Sep 2021 | 2 | -$176,860 | 4 | EVP and CFO | 04 Oct 2021, 20:13 |
| EXEL | EXELIXIS, INC. | 21 Sep 2021 | 3 | -$789,908 | 4 | EVP and CFO | 23 Sep 2021, 20:16 |
| QNCX | Cortexyme, Inc. | 16 Jun 2021 | 1 | $0 | 4 | Director | 17 Jun 2021, 19:32 |